본문 바로가기

EU · EudraLex Vol.4

EU GMP Annex 1 9.33

9. Environmental & process monitoring › Aseptic process simulation (APS) (also known as media fill)

조항 원문

The APS should imitate as closely as possible the routine aseptic manufacturing process and include all the critical manufacturing steps, specifically:

i. The APS should assess all aseptic operations performed subsequent to the sterilisation and decontamination cycles of materials utilised in the process to the point where the container is sealed.

ii. For non-filterable formulations, any additional aseptic steps should be assessed.

iii. Where aseptic manufacturing is performed under an inert atmosphere, the inert gas should be substituted with air in the process simulation unless anaerobic simulation is intended.

iv. Processes requiring the addition of sterile powders should use an acceptable surrogate material in the same containers as those used in the process under evaluation.

v. Separate simulations of individual unit operations (e.g. processes involving drying, blending, milling and subdivision of a sterile powder) should be avoided. Any use of individual simulations should be supported by a documented justification and ensure that the sum total of the individual simulations continues to fully cover the whole process.

vi. The process simulation procedure for lyophilized products should represent the entire aseptic processing chain including filling, transport, loading, a representative duration of the chamber dwell, unloading and sealing under specified, documented and justified conditions representing worst case operating parameters.

vii. The lyophilization process simulation should mimic all aspects of the process, except those that may affect the viability or recovery of contaminants. For instance, boiling-over or actual freezing of the solution should be avoided. Factors to consider in determining APS design include, where applicable:

• The use of air to break vacuum instead of nitrogen or other process gases.

• Replicating the maximum interval between sterilisation of the lyophilizer and its use.

• Replicating the maximum period of time between filtration and lyophilization.

• Quantitative aspects of worst-case situations, e.g. loading the largest number of trays, replicating the longest duration of loading where the chamber is open to the environment.

본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.

출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.